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Abstract Amyloidosis is a collection of systemic dis-
eases characterised by misfolding of previously sol-
uble precursor proteins that become infiltrative de-
positions, thereby disrupting normal organ structure
and function. In the heart, accumulating amyloid fib-
rils lead to progressive ventricular wall thickening and
stiffness, resulting in diastolic dysfunction gradually
progressing to a restrictive cardiomyopathy. The main
types of cardiac amyloidosis are amyloid light chain
(AL) amyloidosis caused by an underlying plasma cell
dyscrasia, amyloid transthyretin (TTR) amyloidosis of
wild-type (normal) TTR at older age (ATTRwt) and
hereditary or mutant amyloid TTR (ATTRm) in which
a genetic mutation leads to an unstable TTR protein.
Overall survival is poor once heart failure develops,
underlining the need for early referral and diagnosis.
Treatment for AL amyloidosis has improved markedly
over the last decades, and TTR amyloidosis gene si-
lencers and orally available transthyretin stabilisers
are ready to enter the clinical arena after recent pos-
itive outcome trials. Novel therapies aiming at fibril
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degradation withmonoclonal antibodies are under in-
vestigation. In this review, we focus on ‘red flag’ signs
and symptoms, diagnosis and management of cardiac
amyloidosis which differs considerably from the gen-
eral management of heart failure. Only by increasing
awareness, prognosis for patients with this devastat-
ing disease can be improved.
Keywords Amyloidosis · Heart · Awareness ·
Diagnosis · Treatment · Left ventricular hypertrophy ·
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Introduction
Amyloidosis is a collection of systemic diseases char-
acterised by misfolding of previously soluble pre-
cursor proteins that become insoluble aggregates
disrupting normal organ structure and function [1].
A large number of precursor proteins are able to form
organised structures called amyloid fibrils [2, 3]. Al-
though these fibrils mainly infiltrate the heart and
kidneys, the peripheral nervous system, gastro-in-
Key messages
 The main types of cardiac amyloidosis are light
chain amyloidosis and transthyretin amyloido-
sis.
 Cardiac amyloidosis should be considered in pa-
tients with:
– heart failure with preserved ejection fraction;
– unexplained left ventricular hypertrophy;
– heart failure refractory to conventional ther-
apy.
 Early diagnosis and therefore increased aware-
ness is necessary to improve outcome.
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Fig. 1 Overview of amy-
loidogenesis, clues for
early diagnosis and treat-
ment of TTR and light
chain cardiac amyloido-
sis. asiRNA (patisiran), an-
tisense oligonucleotide (in-
otersen). btafamidis (se-
lective stabiliser); diflu-
nisal (non-selective sta-
biliser). cantibody-mediated
phagocytosis, doxycycline.
ATTR amyloid transthyretin,
AL amyloid light chain,
TTR transthyretin, FLC free
light chains, HFpEF heart
failure with preserved ejec-
tion fraction, AF atrial fib-
rillation, LVH left ventricu-
lar hypertrophy, GLS global
longitudinal strain,GI gastro-
intestinal, ANS autonomous
nervous system, PNS pe-
ripheral nervous system,
CTS carpal tunnel syn-
drome, SCT stem cell trans-
plantation
testinal tract and soft tissues are also affected (Fig. 1).
The main types of cardiac amyloidosis are amyloid
light chain (AL) amyloidosis caused by an underlying
plasma cell dyscrasia, amyloid transthyretin (ATTR)
amyloidosis of either non-mutant (wild-type) TTR
seen at older age (ATTRwt) and hereditary or mutant
TTR (ATTRm) amyloidosis in which a genetic muta-
tion leads to an unstable transthyretin (TTR) protein
[4]. Accumulating amyloid depositions lead to ven-
tricular wall thickening and diastolic dysfunction,
gradually progressing to a restrictive cardiomyopa-
thy in advanced stage disease. Once diagnosed, the
treatment is two-fold: correcting the underlying amy-
loidogenic process and managing symptoms related
to cardiac (and other organ) involvement. Cardiac
dysfunction is the major determinant of survival, but
diagnosis is often delayed given the aspecific symp-
toms at onset [5, 6].
In this review, we provide an overview of the main
forms of cardiac amyloidosis, its clinical characteris-
tics (Tab. 1), diagnostic approach and management.
Several ‘red flags’ are given to aid clinicians in the
early recognition (Tab. 2). Finally, we discuss specific
considerations on the pharmacological management
of cardiac amyloidosis which differs from the general
management of heart failure (Tab. 3). Suggested fur-
ther reading is summarised in Supplementary Table 1.
The Need For Early Diagnosis
The clinical presentation is variable and education
of physicians is needed to ensure that amyloidosis is
considered as diagnosis [2, 5]. Early diagnosis is cru-
cial for several reasons: a) overall survival is poor once
cardiac involvement is present [7, 8]; b) chemotherapy
followed by stem cell transplantation has improved
prognosis for AL amyloidosis significantly [5, 8]; c) an-
tibody-mediated fibril phagocytosis as well as TTR
gene silencers and protein stabilisers are emerging
including recent positive outcome trials on all-cause
mortality and hospitalisation [9, 10]. Thus, increased
awareness is necessary to improve patient outcome
with this lethal disease.
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Table 1 Main types of cardiac amyloidosis and clinical characteristics
Type Precursor
Protein
Underlying
disorder
Organ
involvement
Sex and age (yrs.) Typical clinical presentation
AL Immunoglobin
light chains
Plasma cell
dyscrasias
Kidney
Heart
Liver
ANS, PNS
Either sex, >50 Heart failure with multi-organ involvement including
nephrotic syndrome, autonomic dysfunction (ortho-
static hypotension, diarrhoea, bladder disorder),
peripheral neuropathy, macroglossia and periorbital
purpura. Severe hypotension after ACEi/ARB
ATTRwt
(‘SSA’)
Wild-type
transthyretin
Ageing Heart Male> Female
>70
Slowly progressive energy decline, exercise intoler-
ance, weight loss and gastro-intestinal complaints.
Left and right sided congestive heart failure with nor-
mal systolic function and clear diastolic dysfunction,
arrythmias.
History of CTS
ATTRm Mutant
transthyretin
TTR gene muta-
tion
Nervous systema
Heart
Male> Female >40b Slowly progressive heart failure symptoms (as in
ATTRwt) with (invalidating) peripheral or autonomic
neuropathy. Family history of neurological disease
AL amyloid light chain, ATTRwt wild-type amyloid transthyretin, ATTRm mutant amyloid transthyretin, SSA senile systemic amyloidosis, ANS autonomic nervous
system, PNS peripheral nervous system, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CTS carpal tunnel syndrome
aAutonomic and peripheral nervous system involvement can lead to similar symptoms as in AL amyloidosis
bMutation dependent, African-Americans with V122I may present at an older age around >60 years
Table 2 Red flags for suspicion of cardiac amyloidosis
Diagnostic Red flag
History taking Carpal tunnel syndrome (bilateral) in an elderly patient with increased wall thickness on echocardiography, family history of
neuropathy or SCD;
Complaints of sensory peripheral neuropathy, foamy urine and or bleeding
ECG Low QRS voltage or disproportionally low voltage in the presence of increased left ventricular wall thickness/LVH
ECG Pseudo-infarct pattern in the absence of wall motion abnormalities on echocardiography
Echocardiography Symmetrical LVH (and RVH) in the absence of aortic stenosis or longstanding hypertension
Echocardiography Preserved LVEF, but reduced GLS with apical sparing (see also Fig. 1)
CMR Transmural or subendocardial LGE not related to a coronary artery territory, diffuse atrial LGE, RV LGE, suboptimal nulling
CMR Increased native T1 values, increased extracellular volume, myocardial oedema (T2)
Laboratory testing Disproportionally high level of NT-proBNP, chronically elevated troponin at low level with normal CAG
SCD sudden cardiac death, ECG electrocardiogram, LVH left ventricular hypertrophy, RVH right ventricular hypertrophy, LVEF left ventricular ejection fraction,
GLS global longitudinal strain, CMR cardiac magnetic resonance, LGE late gadolinium enhancement, RV right ventricle, CAG coronary angiography
Table 3 Pharmacological management in cardiac amyloidosis
Clinical situation Medication Comment
Fluid retention, oedema and
orthopnoea
Loop diuretic, often combined with mineralocorticoid
receptor antagonist (MRA)
Careful titration, avoid underfilling
Supraventricular arrhythmias
(atrial fibrillation/flutter)
β-blocker Only in case of very high heart rate; generally to be avoided
due to rate-dependent maintenance of cardiac output in
advanced stage
Amiodaron Generally well tolerated.
Capable of keeping sinus rhythm
Non-dihydropyridine calcium channel blockers
(i.e. verapamil, diltiazem)
Contra-indicated as toxicity may occur quickly due to abnor-
mal binding to amyloid fibrils;
Same effect as with β-blocker
Digoxin Contra-indicated as toxicity may occur quickly due to abnor-
mal binding to amyloid fibrils
Anticoagulant therapy Should be considered even in sinus rhythm or low
CHA2DS2VASC score due to a high risk of atrial thrombus
in case of atrial dysfunction
QT-prolonging medication Especially antipsychotics (haloperidol, quetiapine, olanza-
pine), tricyclic antidepressants (amitriptyline, nortriptyline,
citalopram), anti-emetics (metoclopramide, ondansetron),
antibiotics (ciproxin, azoles)a
Should be used with careful monitoring of QRS duration
aFor a complete list of QT-prolonging mediation, see www.QTdrugs.org
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Epidemiology
Cardiac amyloidosis was previously regarded a rare
condition. AL cardiac amyloidosis (AL-CA) is the most
prevalent type responsible for ±70% of all newly diag-
nosed patients with cardiac amyloidosis [2, 11]. A lim-
ited number of epidemiologic studies have been re-
ported, but the incidence of AL amyloidosis in the
Western world is 8–12 per million persons per year
[5, 11]. Data on ATTR amyloidosis are even more
sparse; a recent Swedish study reported an incidence
of 2.0 per million inhabitants per year [12]. However,
it is commonly overlooked due to the more gradual
course and aspecific symptoms in the elderly. Un-
derlying ATTR cardiac amyloidosis (ATTR-CA) is fre-
quently present in patients with aortic stenosis (~10%)
and heart failure with preserved ejection fraction (HF-
pEF) aged 75 or older, although the clinical relevance
of amyloid depositions reported on autopsy remains
unknown [13–15]. Using bone scintigraphy ATTR-CA
was detected in 13% of patients with HFpEF and in
10% of patients who recently underwent carpal tun-
nel surgery [16, 17]. Prevalence of cardiac amyloidosis
is increasing due to better imaging modalities and the
aging population [5, 11].
Clinical Characteristics
Cardiac symptoms
Patients with cardiac amyloidosis develop diastolic
dysfunction leading to HFpEF complaining of fatigue,
shortness of breath and oedema [2, 8, 18]. Syncope
on exertion may occur due to the ‘fixed’ and relatively
low stroke volume next to conduction disorders (bun-
dle branch block and/or atrioventricular block) after
infiltration of the conduction system. Depositions
in the small (coronary) vessels, may lead to angina
and jaw or leg claudication. Atrial dysfunction and
atrial fibrillation due to atrial amyloid depositions
may cause thromboembolism requiring antithrom-
botic therapy. Heart failure symptoms, left ventricular
hypertrophy on imaging and signs and symptoms of
other organ involvement offer an important clue, as
summarised in Tab. 2.
AL amyloidosis
AL amyloidosis is a primary haematological multi-
organ disease, although heart and kidneys (70–80%)
are predominately affected, presenting at the age of
55–60 [7, 8, 19]. Especially renal involvement leading
to nephrotic syndrome may be the first manifestation
next to peripheral neuropathy, autonomous dysfunc-
tion and gastro-intestinal complaints (Tab. 1; [1, 2]).
Periorbital bruising and macroglossia are considered
pathognomic but relatively rare. An important clue
for cardiologists is severe hypotension after initiation
of angiotensin-converting enzyme (ACE) inhibitors or
angiotensin receptor blocker (ARB) therapy or clinical
deterioration after introduction of β-blockade. Iso-
lated cardiac amyloidosis is found in approximately
5%. Carpal tunnel syndrome is less common then in
ATTR amyloidosis. Multiple myeloma can be identi-
fied in 10–15%, but most patients have <20% plasma
cells with bone marrow biopsy. Severe cardiac in-
volvement at diagnosis often prevents patients from
getting optimal therapy leading to a median survival
of 6–12 months, which is worse than in ATTR-CA and
probably caused by direct cardiotoxic effects of light
chains [6, 20]. Moderate or little cardiac involvement
has a much better outcome.
ATTR amyloidosis
In ATTRwt amyloidosis, the misfolding of TTR is asso-
ciated with age (formerly called senile systemic amy-
loidosis, SSA), mainly affecting the heart, although it
has a systemic distribution [21]. Depositions in other
organs are generally well tolerated, mean age at pre-
sentation is >70 years predominantly in males com-
plaining of heart failure or atrial arrhythmias and con-
duction disorders. Asymmetrical left ventricular hy-
pertrophy and ejection fraction <50% do occur and
women are affected in 20% of cases [22]. As shown in
Tab. 2, carpal tunnel syndrome is an important clue
[1, 18]. Median survival is about 5 years from diagno-
sis. In ATTRm amyloidosis, the rate of cardiac versus
neurological involvement depends on the underlying
TTR mutation of which over 100 have been identified
[23]. The most common mutations are the valine-to-
isoleucine mutation at position 122 (Val122I), carried
by 3–4% of the African-Americans leading to late-on-
set cardiac amyloidosis and the Val30Met mutation
with a high prevalence in northern Portugal and Swe-
den [24]. The Thr60Ala (Ireland), Leu111Met (Den-
mark) and Ile68Leu (Italy) mutations have a more ma-
lignant course with onset at the age of 40 [5, 21]. The
clinical presentation is comparable to ATTRwt amy-
loidosis with the addition of peripheral or autonomic
nervous system involvement (Tab. 2); overall survival
is estimated at 5–8 years [23].
Diagnosis Of Cardiac Amyloidosis
‘Red flag’ signs and symptoms contribute to early
recognition (Tab. 2) and suspicion should increase
in patients with unexplained HFpEF and/or left ven-
tricular hypertrophy [2, 5, 8]. Data on diagnostic
performance are mostly lacking. The reader is re-
ferred to a pooled cohort covering clinical findings,
a recent meta-analysis on bone scintigraphy and the
Supplementary Table 1 [17, 22].
In Fig. 4, a diagnostic flow chart is provided to
establish either AL-CA or ATTR-CA. The differen-
tial diagnosis consists of the most common genetic
and non-genetic disorders causing a hypertrophic
cardiomyopathy, next to the easily excluded long-
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Fig. 2 Echocardiography in cardiac amyloidosis. a–bGranu-
lar echogenic appearance of the left ventricular wall with clear
hypertrophy and some pericardial effusion. Left ventricular
ejection fraction is preserved (c), septal tissue Doppler longi-
tudinal movement is reduced (d). Longitudinal strain analysis
from the 3 apical views showing characteristic apical sparing
(bull’s eye) with reduced strain at the mid and basal level (e)
standing hypertension and aortic stenosis. Impor-
tantly, aortic stenosis and clonal immunoglobulin
abnormalities may coexist with ATTR-CA [5, 7, 22].
For adequate typing, the combination of bone scintig-
raphy and testing for monoclonal proteins is crucial
[2, 5]. Especially in AL amyloidosis, timely diagnosis
is essential for therapeutic outcome.
Electrocardiography
The typical ECG in cardiac amyloidosis is charac-
terised by low QRS voltage due to amyloid infiltration,
seen in approximately 50–60% in AL-CA but in only
20% in ATTR-CA [6, 8]. Therefore, an important clue is
a discrepancy between the left ventricular wall thick-
ness and QRS voltage (red flag, Tab. 2). In approx-
imately 50–70% of patients pseudo-infarct patterns
are present, eventually leading to unnecessary coro-
nary angiography (red flag, Tab. 2; [22]). The P wave
may reflect prolonged atrial conduction or atrial di-
latation. Conduction disorders occur frequently, the
presence of atrioventricular block in patients with left
ventricular hypertrophy should raise suspicion.
Echocardiography
Echocardiographic findings in cardiac amyloidosis
are a classic example of an infiltrative cardiomyopa-
thy. Increased echogenicity (i.e. granular or ‘speckled’
myocardium) had good sensitivity and specificity
using fundamental imaging before harmonic imag-
ing was introduced and is not reliable anymore [5,
25]. Major findings are increased left ventricular
wall thickness (>12mm, either symmetrical or asym-
metrical) in combination with the right ventricular
free wall, thickened valves and pericardial effusion
(Fig. 2). Global longitudinal left ventricular strain
analysis may reveal a pattern of prognostically im-
portant apical ‘sparing’, but the specificity for cardiac
amyloidosis needs further study. Left ventricular
ejection fraction (LVEF) is mostly preserved (red flag,
Tab. 2; [25]). Reduced tissue Doppler velocities of the
mitral annulus are common, diastolic dysfunction is
frequently present including a restrictive physiology:
high E/A ratio, even absence of the A wave, shortened
deceleration time, high E/e’ and severely increased
atrial volumes. Importantly, atrial dysfunction can
also be demonstrated by an abnormal left atrial strain
and may lead to the formation of thrombi even in the
absence of atrial fibrillation (atrial standstill) [26].
Cardiac magnetic resonance (CMR)
The advantage of CMR, besides a higher resolution, is
the possibility to further characterise the myocardium
using late gadolinium enhancement (LGE) imaging
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Fig. 3 Cardiac magnetic
resonance imaging in car-
diac amyloidosis. a–b Car-
diac magnetic resonance
imaging showing a 4-cham-
ber and short axis view with
left ventricular hypertro-
phy mainly in the septal re-
gion. Corresponding short
axis view showing gener-
alised subendocardial late
gadolinium enhancement
not fitting a coronary terri-
tory. Note the reduced sig-
nal of the blood pool (dark
blood), which is specific
for cardiac amyloidosis (c).
Native T1 mapping analy-
sis showing an increased
T1 value of 1214± 31ms (d)
and subsequent ECV map
which is increased giving
a value of 51± 2.8% (e),
both acquired with a field
strength of 1.5T
and T1 mapping, a quantitative technique able to de-
tect diffuse myocardial abnormalities including amy-
loid burden [27]. Transmural or subendocardial LGE
not fitting a coronary artery territory or including the
right ventricle may be the first clue, next to subopti-
mal nulling due to altered gadolinium kinetics (Fig. 3).
Native T1 mapping (before contrast) is typically pro-
longed. Postcontrast T1 mapping is decreased as the
myocardial tissue reaches the null crossing at an ear-
lier or similar inversion time as the blood pool, sub-
sequently resulting in an increased extracellular vol-
ume (ECV) generally >40% (red flag, Tab. 2). In both
ATTR-CA and AL-CA, T2 values indicative of myocar-
dial oedema are increased and T2 is a predictor of
prognosis in AL-CA [28]. CMR, similar to echocar-
diography, cannot differentiate between amyloidosis
types.
Nuclear imaging
Phosphate-based technetium tracers (99mTc-PYP,
99mTc-MDP, 99mTc-DPD), normally used for bone
scintigraphy, accumulate in the presence of ATTR-CA
although the exact mechanism is unclear. Uptake in
AL-CA, Fabry disease and hypertrophic cardiomyopa-
thy is absent or low [17]. Visual grading is based on
the work by Perugini ranging from grade 0 (no uptake)
to grade 3 if cardiac uptake is higher than in bone
[29]. Grade 2 and 3 uptake in the absence of a mono-
clonal protein showed a 100% specificity and positive
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Cardiac symptoms
Unexplained HFpEF
Dyspnoea, oedema
Unexplained fague 
Palpitaons (AF/SVT)
Syncope (on exeron)
Unexplained LVH
Exclude hypertension, 
endocrine disorders, chronic 
drug use (steroids, tacrolimus, 
hydroxychloroquine), HCM, AS.
Beware of coexisng AS.
Systemic manifestaons
Nephroc syndrome
Autonomic dysfuncon
Carpal tunnel syndrome
Gastro-intesnal complaints
Peripheral neuropathy
Suspected ECG, echocardiogram and/or CMR ﬁndings (red ﬂags)
No uptake (grade 0), 
negave screening
AL/ATTR cardiac 
amyloidosis unlikely.
Reconsider diﬀerenal 
diagnosis including HCM, 
inherited metabolic or 
mitochondrial and 
malformaon syndromes. 
Strong uptake (≥grade 
2), negave screening
ATTR cardiac amyloidosis.
Perform TTR sequencing to 
diﬀerenate between 
mutant or wild-type ATTR. 
Extend if indicated to rule 
out other forms of HCM.
No uptake (grade 0), 
posive screening
AL cardiac amyloidosis 
likely. 
Referral to haematologist for 
fat or bone marrow biopsy.
EMB may sll be necessary 
for ﬁnal diagnosis.
Uptake ≥ grade 1 ± 
posive screeningb
Requires further typing 
EMB with IHC (+MS)
AL/ATTR and other types (i.e. 
AA, AApoA1) possible.
Consider ATTR with 
coexisng MGUS (±20%).
When in doubt or clinical suspicion remains, always consider EMB for exclusionand/or speciﬁc amyloid typing using IHC/MS.
Bone scingraphy + screening for monoclonal proteina
Fig. 4 Flow chart for the diagnosis of cardiac amyloido-
sis. aserum-free light chain assay, serum/urine immunofixa-
tion. bPerugini grade 1 or 2 with or w/o positive AL amyloido-
sis screening, grade 3 with positive AL amyloidosis screen-
ing. HFpEF heart failure with preserved ejection fraction,
AF atrial fibrillation, SVT supraventricular tachycardia, LVH left
ventricular hypertrophy, HCM hypertrophic cardiomyopathy,
AS aortic stenosis, ECG electrocardiogram, CMR cardiac
magnetic resonance, AL amyloid light chain, ATTR amyloid
transthyretin, EMB endomyocardial biopsy, IHC immunohisto-
chemistry, MS mass spectrometry, AA amyloid serum A pro-
tein, AApoA1 amyloid apolipoprotein A1, MGUS monoclonal
gammopathy of unknown significance, TTR transthyretin
predictive value for ATTR-CA without the need for ad-
ditional histology [30]. Importantly, in all other cases
(i.e. low-grade uptake, positive light chains) cardiac
and/or tissue biopsy is necessary to rule out AL-CA
and more rare forms of amyloidosis (AA, AApoA1) [3].
Although positive emission tomography (PET) using
18F-Florbetapir and 11C-PiB to image β-amyloid looks
promising, it is not routinely used yet [31, 32].
Endomyocardial biopsy (EMB)
In case of ongoing clinical suspicion, nuclear imaging
with low-grade or high-grade tracer uptake in com-
bination with positive monoclonal protein, EMB is
necessary to correctly type the underlying amyloido-
sis (Fig. 4). EMB should be performed by experienced
clinicians and trained pathologists. Congo red will
demonstrate amyloid depositions as red staining un-
der bright light and shows apple-green birefringences
under polarised light, which should be followed by
immunohistochemistry. Mass spectrometry after laser
dissection is increasingly being used to determine the
specific amyloid type especially when there is also
some degree of monoclonal gammopathy [3, 7].
Laboratory testing, biomarkers, tissue biopsy and
genetic testing
Standard laboratory screening may reveal kidney and
liver involvement. Serum/urine immunofixation in
combination with a serum-free light chain assay will
evaluate light chain abnormalities [1, 8]. In chronic
kidney disease impaired renal filtration leads to al-
tered κ/λ ratios [5]. N-terminal prohormone brain
natriuretic peptide (NT-proBNP) levels are often el-
evated to a disproportionally high levels due to toxi-
city of the precursor proteins (red flag, Tab. 2). Tro-
ponins are chronically elevated without rise/fall. Both
troponin and NT-proBNP have prognostic implica-
tions in AL-CA and in ATTR-CA [20, 33]. Importantly,
diagnosing AL-CA based on plasma dyscrasias and
a positive tissue biopsy alone can be insufficient since
20% of patients with ATTR-CA also have a non-re-
lated clonal immunoglobulin abnormality [7]. When
AL amyloidosis is suspected, final diagnosis is estab-
lished in close collaboration with the haematologists
for which a bone marrow biopsy is essential to con-
firm plasma cell dyscrasia. If a fat biopsy is performed,
a negative result does not rule out amyloidosis be-
cause of lower sensitivity [23]. In case of ATTR-CA,
TTR gene sequencing is recommended to confirm or
exclude ATTRm, as well as other forms of hypertrophic
cardiomyopathy, if indicated.
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Therapy
After diagnosis, staging is necessary to assess treat-
ment eligibility and prognosis [34]. This is based on
the Mayo Clinic system for AL amyloidosis using tro-
ponin, NT-proBNP and serum-free light chain and
performance scale [20, 35]. The revised European
staging also includes a subgroup of stage IIIb (NT-
proBNP >8500pg/ml) and a dismal prognosis. For
ATTR amyloidosis, estimated glomerular filtration rate
(eGFR) reflecting renal dysfunction was suggested to
improve stratification [21, 33]. Therapeutic goals are
the management of heart failure and interfering with
the underlying amyloidogenic process [5, 6].
Cardiac supportive therapy
Pharmacological management in cardiac amyloidosis
is different from the general management of heart
failure as commonly used medication can have im-
portant negative consequences (Tab. 3). Diuretics are
the cornerstone in symptom management often com-
bined with mineralocorticoid receptor antagonists.
This is more challenging in AL-CA with multiple or-
gans affected, giving an increased risk for renal failure
or orthostatic hypotension. To avoid underfilling,
sodium and fluid restriction are important to keep
patients euvolemic with the smallest amount of di-
uretics possible [8]. Midodrine is sometimes used
to treat orthostatic hypotension, ACE inhibitors and
ARB are poorly tolerated especially in AL-CA [7]. The
use of β-blockers should generally be avoided; an
increased heart rate is the only way to maintain ad-
equate cardiac output in advanced disease. Non-
dihydropyridine calcium channel blockers (i.e. vera-
pamil, diltiazem) and digoxin are contra-indicated as
toxicity may occur quickly due to abnormal binding
to amyloid fibrils [36, 37]. In case of supraventric-
ular arrhythmias, amiodarone should be considered
next to catheter ablation. Importantly, anticoagu-
lation should be considered even in patients with
sinus rhythm or low CHA2DS2VASC score (congestive
heart failure, hypertension, age ≥75 years [doubled],
diabetes mellitus, prior stroke [doubled]-vascular
disease, age 65–74, sex category) given the high in-
cidence of atrial thrombi (atrial standstill), although
randomised trials are lacking [26]. Careful monitoring
for thrombocytopenia is necessary after chemother-
apy in AL-CA. Ventricular arrhythmias do occur, but
implantable cardioverter defibrillator (ICD) therapy is
usually not indicated as sudden cardiac death (SCD)
is mostly caused by bradycardia or adequate rhythm
with pulseless electrical activity [38, 39]. According to
the general guidelines for bradypacing, implantation
of a pacemaker should be considered, but it remains
unclear whether this prevents SCD. QT-prolonging
medication should be given under careful monitor-
ing, as especially anti-emetics or QT-prolonging pro-
phylactic antibiotics necessary during chemotherapy
can be challenging. Finally, only in highly selected
patients a heart transplantation may be considered
in isolated AL-CA in combination with chemotherapy
and stem cell transplantation. Widespread experi-
ence is lacking and this has not been performed in
the Netherlands [40].
Treatment of AL amyloidosis
Patients must be referred to the haematologist to
initiate chemotherapy targeting the clonal plasma
cells [7, 34]. Treatment-related mortality is high as
the treatment by itself can be cardiotoxic leading to
worsening heart failure. Although chemotherapy fol-
lowed by autologous stem cell transplantation (SCT)
is the preferred therapy to obtain complete remission,
only a minority of patients are eligible after patient
selection [7, 8, 41]. Severe cardiac involvement is an
important contraindication (serum NTproBNP level
is >5000pg/ml, serum troponin T level is >0.06ng/ml,
LVEF <45%, New York Heart Association [NYHA]
class≥ III) next to severe kidney dysfunction, hy-
potension, age >70 years and impaired performance
status [34, 35].
Treatment of ATTR amyloidosis
Although classically seen as a lethal disease without
specific treatment, several disease-modifying drugs
have been developed recently interfering at differ-
ent points in the TTR amyloidogenesis pathway [5].
Gene silencers interfere with TTR protein synthesis
in the liver including patisiran, a small interfering
ribonucleicacid (siRNA) in a lipid nanoparticle target-
ing hepatocytes. Patisiran reduced TTR protein levels
in ATTRm patients with neuropathy slowing disease
progression (Apollo phase III trial) and led to a re-
duction in hospitalisation and/or all-cause mortality
in the ATTR-CA[10]. Inotersen, an antisense oligonu-
cleotide, showed substantial benefit in ATTRm pa-
tients with polyneuropathy but safety concerns were
raised as thrombocytopenia and glomerulonephritis
were reported [42]. Next to gene silencing, stabilisers
preventing TTR dissociation have been investigated.
Diflunisal, an old non-steroidal anti-inflammatory
drug (NSAID) stabilising the TTR tetramer in patients
with ATTRm and polyneuropathy showed a reduction
in the rate of progression [43]. It was reasonably
tolerated in a small open-labelled study, but larger
trials assessing common NSAID side effects (gastro-
intestinal bleeding, kidney dysfunction, worsening
heart failure) are necessary [44]. Recently, a mul-
ticentre placebo-controlled phase III study showed
a reduction of all-cause mortality and hospitalisa-
tions in both ATTRm and ATTRwt patients treated
with the oral TTR stabiliser tafamidis [9]. Other
potential options are Green Tea extract, capable of
stabilising the TTR protein, and doxycycline com-
bined with biliary acid, lowering TTR depositions.
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However, these compounds have only been studied
in small animal models and an open label study with
20 patients [45]. Liver transplantation in ATTRm is
an option in selected cases without cardiac involve-
ment, but timing of this major operation is difficult
and follow-up showed an accelerated occurrence of
wild-type ATTR after transplantation with extensive
cardiac depositions [11].
Emerging therapies for amyloid fibril degradation
Several trials are underway investigating the appli-
cation of antibodies recognising amyloid fibrils to
induce phagocytosis including an anti-amyloid an-
tibody 11-1F4 (phase I, NCT02245867) and serum
amyloid P (SAP) antibody (phase I, NCT01777243)
although some safety issues remain to be investi-
gated [5, 46]. Investigation of NEOD001 (phase III,
NCT02312206), an antibody targeting circulating and
deposited amyloid, was discontinued after a negative
futility analysis [47]. Another option is doxycycline
showing an inhibitory effect on fibrillogenesis in
transgenic AL amyloidosis mice as well as in stage III
AL-CA patients in a small retrospective study leading
to increased survival [48]. A prospective trial inves-
tigating doxycycline is currently enrolling patients
[49].
Conclusions and Outlook
Major advancements have been made in the past
decade in the treatment of cardiac amyloidosis. Es-
pecially AL-CA is a medical emergency and new
chemotherapeutic regimens followed by stem cell
transplantation have improved prognosis consider-
ably. For ATTR-CA, TTR gene silencers and stabilisers
are awaiting approval by the National Health Care
Institute (Zorginstituut Nederland), giving patients
high expectations. Monoclonal antibodies facilitat-
ing breakdown of existing depositions would provide
a major breakthrough, making this a reversible dis-
ease. Patients will benefit the most if cardiac amyloi-
dosis is diagnosed early, requiring timely referral and
work-up in an experienced centre using a multidis-
ciplinary approach. The accompanying costs ask for
future cost/benefit analyses (i.e. close monitoring in
a national registry) to provide more information on
who benefits the most.
Early diagnosis is important given the emerging
therapies. If we can increase awareness, the land-
scape for patients with cardiac amyloidosis will def-
initely change.
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